内容紹介
Summary
We conducted a retrospective comparative study on feasibility of S-1/oxaliplatin(SOX)therapy and S-1/cisplatin therapy with short hydration(SP-SH)for gastric cancer in the outpatient setting. The subjects were patients with gastric cancer aged younger than 75 years who underwent SOX or SP-SH therapy at our hospital. There were 22 patients in the SOX group and 30 patients in the SP-SH group. Both the groups received the first course during hospitalization and then received the subsequent courses in the outpatient section. Evaluation items for each therapy included the treatment rate in the outpatient setting, number of re-hospitalization cases, relative dose intensity(RDI), and adverse events. The treatment rate in the outpatient setting was 100%(22/22)in the SOX group and 96% in the SP-SH group(26/27). Re-hospitalization cases included 1 case of loss of appetite in the SOX group and 1 cases of loss of appetite and 2 cases of febrile neutropenia(FN)in the SP-SH group. The median values of the RDI were 86% with S-1 and 85% with oxaliplatin in the SOX group and 92% with S-1 and 80% with cisplatin in the SP-SH group. The SP-SH group had a higher proportion of neutropenia cases of Grade 3 or higher(SP-SH 33% v. s SOX 5%, p=0.012). The SOX group showed a higher proportion of loss of appetite cases for all the Grades(SOX 86% v. s SP-SH 50%, p=0.007)and peripheral neuropathy cases(SOX 64% v. s SP-SH 23%, p=0.003). It was considered that SOX and SP-SH therapies can be treated in the outpatient section, although the occurrence of loss of appetite and FN must be considered.
要旨
胃癌に対するS-1/oxaliplatin(SOX)療法とshort hydration法によるS-1/cisplatin(SP-SH)療法の外来投与における忍容性について,後方視的に比較検討を行った。対象は当院でSOX療法またはSP-SH療法を施行した75歳未満の胃癌患者で,SOX群は22例,SP-SH群は30例とした。ともに1コース目を入院で施行し,次コースより外来実施を試みた。各療法の外来施行率,再入院症例数,薬剤相対用量強度(relative dose intensity: RDI)と有害事象を評価した。2コース以上施行した症例における外来施行率はSOX群で100%(22/22例),SP-SH群で96%(26/27例)であった。再入院を要した症例はSOX群で食欲不振1例,SP-SH群では食欲不振1例,発熱性好中球減少症(FN)2例であった。RDI中央値はSOX群でS-1が86%,oxaliplatin 85%,SP-SH群でS-1 92%,cisplatinが80%であった。SP-SH群ではGrade 3以上の好中球減少が多かった(SP-SH 33% v. s SOX 5%,p=0.012)。SOX群では,全Gradeの食欲不振(SOX 86% v. s SP-SH 50%,p=0.007)と末梢神経障害(SOX 64% v. s SP-SH 23%,p=0.003)が多かった。SOX療法,SP-SH療法は食欲不振,FNに留意を要するが,ともに外来で施行可能なレジメンであった。
目次
We conducted a retrospective comparative study on feasibility of S-1/oxaliplatin(SOX)therapy and S-1/cisplatin therapy with short hydration(SP-SH)for gastric cancer in the outpatient setting. The subjects were patients with gastric cancer aged younger than 75 years who underwent SOX or SP-SH therapy at our hospital. There were 22 patients in the SOX group and 30 patients in the SP-SH group. Both the groups received the first course during hospitalization and then received the subsequent courses in the outpatient section. Evaluation items for each therapy included the treatment rate in the outpatient setting, number of re-hospitalization cases, relative dose intensity(RDI), and adverse events. The treatment rate in the outpatient setting was 100%(22/22)in the SOX group and 96% in the SP-SH group(26/27). Re-hospitalization cases included 1 case of loss of appetite in the SOX group and 1 cases of loss of appetite and 2 cases of febrile neutropenia(FN)in the SP-SH group. The median values of the RDI were 86% with S-1 and 85% with oxaliplatin in the SOX group and 92% with S-1 and 80% with cisplatin in the SP-SH group. The SP-SH group had a higher proportion of neutropenia cases of Grade 3 or higher(SP-SH 33% v. s SOX 5%, p=0.012). The SOX group showed a higher proportion of loss of appetite cases for all the Grades(SOX 86% v. s SP-SH 50%, p=0.007)and peripheral neuropathy cases(SOX 64% v. s SP-SH 23%, p=0.003). It was considered that SOX and SP-SH therapies can be treated in the outpatient section, although the occurrence of loss of appetite and FN must be considered.
要旨
胃癌に対するS-1/oxaliplatin(SOX)療法とshort hydration法によるS-1/cisplatin(SP-SH)療法の外来投与における忍容性について,後方視的に比較検討を行った。対象は当院でSOX療法またはSP-SH療法を施行した75歳未満の胃癌患者で,SOX群は22例,SP-SH群は30例とした。ともに1コース目を入院で施行し,次コースより外来実施を試みた。各療法の外来施行率,再入院症例数,薬剤相対用量強度(relative dose intensity: RDI)と有害事象を評価した。2コース以上施行した症例における外来施行率はSOX群で100%(22/22例),SP-SH群で96%(26/27例)であった。再入院を要した症例はSOX群で食欲不振1例,SP-SH群では食欲不振1例,発熱性好中球減少症(FN)2例であった。RDI中央値はSOX群でS-1が86%,oxaliplatin 85%,SP-SH群でS-1 92%,cisplatinが80%であった。SP-SH群ではGrade 3以上の好中球減少が多かった(SP-SH 33% v. s SOX 5%,p=0.012)。SOX群では,全Gradeの食欲不振(SOX 86% v. s SP-SH 50%,p=0.007)と末梢神経障害(SOX 64% v. s SP-SH 23%,p=0.003)が多かった。SOX療法,SP-SH療法は食欲不振,FNに留意を要するが,ともに外来で施行可能なレジメンであった。